Drugs / Copper-64 labeled Granzyme B
Copper-64 labeled Granzyme B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05888532 | May 2023 → Dec 2026 expected | kidney cancer, prostate carcinoma, urethra cancer | Rahul Aggarwal | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Copper-64 labeled Granzyme B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05888532 ↗ |
| Modality | Diagnostic / imaging agent | “radiotracer” NCT05888532 ↗ |
| Route | Intravenous | “Given IV prior to imaging” NCT05888532 ↗ |